Locoregional treatment of malignant hepatic tumors with biologic response modifiers.
Locoregional delivery of biologic response modifiers (BRMs) to hepatic tumors is an appealing approach to increase the dwell time of BMRs, to minimize the systemic toxicity, and to induce local and possibly systemic immune responses against tumor cells. Previous clinical studies using this approach showed some encouraging results. However, a large-scale clinical trial is needed to prove the efficacy of locoregional BMR treatment in primary and metastatic hepatic tumors. Combination of various BRM agents with appropriate treatment modalities might further improve the efficacy of locoregional BMR treatment. Additionally, we need to collect more information regarding the host immune response and change in tumor microenvironment after delivering BMRs to hepatic tumors.
Yamamoto
Akira
A
Department of Medical Oncology, Jefferson Medical College of Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA 19107, USA.
Sato
Takami
T
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D007167:Immunotherapy / Q000379:methods*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality
D000970:Antineoplastic Agents; D007155:Immunologic Factors